Australia
· Delayed Price · Currency is AUD Firebrick Pharma Statistics
Total Valuation
Firebrick Pharma has a market cap or net worth of AUD 11.77 million. The enterprise value is 10.94 million.
| Market Cap | 11.77M |
| Enterprise Value | 10.94M |
Important Dates
The last earnings date was Thursday, November 28, 2024.
| Earnings Date | Nov 28, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Firebrick Pharma has 210.11 million shares outstanding. The number of shares has increased by 5.25% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 210.11M |
| Shares Change (YoY) | +5.25% |
| Shares Change (QoQ) | +3.01% |
| Owned by Insiders (%) | 35.94% |
| Owned by Institutions (%) | n/a |
| Float | 104.94M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.65 |
| PB Ratio | 5.17 |
| P/TBV Ratio | 5.56 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -9.30 |
| EV / Sales | 3.98 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -4.67 |
Financial Position
The company has a current ratio of 7.19
| Current Ratio | 7.19 |
| Quick Ratio | 6.10 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1,084.28 |
Financial Efficiency
Return on equity (ROE) is -51.22% and return on invested capital (ROIC) is -29.73%.
| Return on Equity (ROE) | -51.22% |
| Return on Assets (ROA) | -25.33% |
| Return on Capital (ROIC) | -29.73% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 1.02 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +12.00% in the last 52 weeks. The beta is 1.68, so Firebrick Pharma's price volatility has been higher than the market average.
| Beta (5Y) | 1.68 |
| 52-Week Price Change | +12.00% |
| 50-Day Moving Average | 0.06 |
| 200-Day Moving Average | 0.06 |
| Relative Strength Index (RSI) | 46.77 |
| Average Volume (20 Days) | 80,587 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Firebrick Pharma had revenue of AUD 2.75 million and -1.18 million in losses. Loss per share was -0.01.
| Revenue | 2.75M |
| Gross Profit | 2.71M |
| Operating Income | -1.09M |
| Pretax Income | -1.18M |
| Net Income | -1.18M |
| EBITDA | -1.08M |
| EBIT | -1.09M |
| Loss Per Share | -0.01 |
Balance Sheet
| Cash & Cash Equivalents | 824,776 |
| Total Debt | n/a |
| Net Cash | 824,776 |
| Net Cash Per Share | 0.00 |
| Equity (Book Value) | 2.12M |
| Book Value Per Share | 0.01 |
| Working Capital | 1.80M |
Cash Flow
In the last 12 months, operating cash flow was -2.34 million and capital expenditures -134, giving a free cash flow of -2.35 million.
| Operating Cash Flow | -2.34M |
| Capital Expenditures | -134 |
| Free Cash Flow | -2.35M |
| FCF Per Share | -0.01 |
Margins
Gross margin is 98.64%, with operating and profit margins of -39.70% and -42.75%.
| Gross Margin | 98.64% |
| Operating Margin | -39.70% |
| Pretax Margin | -42.75% |
| Profit Margin | -42.75% |
| EBITDA Margin | -39.44% |
| EBIT Margin | -39.70% |
| FCF Margin | n/a |
Dividends & Yields
Firebrick Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -5.25% |
| Shareholder Yield | -5.25% |
| Earnings Yield | -11.73% |
| FCF Yield | -19.93% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Firebrick Pharma has an Altman Z-Score of 24.02.
| Altman Z-Score | 24.02 |
| Piotroski F-Score | n/a |